Cidara Therapeutics recently announced that its lead antiviral candidate, CD388, advanced into Phase 3 development and received FDA Breakthrough Therapy designation, with the company also securing up ...
23h
How Will Fortive's (FTV) Operational Streamlining and Share Buybacks Shape Its Investment Narrative?
Fortive Corporation reported third quarter 2025 results showing revenue of US$1,027.1 million and net income of US$55 million, while also highlighting operational streamlining efforts and continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback